Table 3. Univariate and multivariate analyses of clinical factors for survival after cytoreductive surgery by the proportional hazard model.
Univariate analysis | Multivariate analysis | ||||||
---|---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P values | Hazard ratio | 95% CI | P values | ||
Age at recurrence | (continuous variable) | 1.001 | 0.97–1.03 | 0.96 | – | – | – |
Interval between surgeries | (continuous variable) | 0.993 | 0.97–1.01 | 0.47 | – | – | – |
Preoperative KPS | <80% | 1 | 1 | ||||
80–100% | 0.43 | 0.14–1.35 | 0.15 | 1.20 | 0.31–4.54 | 0.78 | |
KPS change after surgery | decrease | 1 | 1 | ||||
stable | 0.24 | 0.09–0.66 | 0.005 | 0.22 | 0.07–0.71 | 0.01* | |
Extent of Resection (%) | (continuous variable) | 0.98 | 0.95–1.02 | 0.37 | – | – | – |
BCNU wafer implantation | no | 1 | 1 | ||||
yes | 0.48 | 0.19–1.17 | 0.11 | 1.12 | 0.37–3.46 | 0.84 | |
BEV available after surgery | yes | 1 | 1 | ||||
no | 3.19 | 1.27–7.98 | 0.013 | 3.34 | 1.11–10.1 | 0.03* |
BEV: bevacizumab, CI: confidence interval, KPS: Karnofsky Performance Status.